Exploration of a new model for the construction of medical institution formulation platforms from the perspective of industry-university-research collaborative innovation theory
- VernacularTitle:产学研协同创新理论视角下医疗机构制剂平台建设新模式探索
- Author:
Kana LIN
1
;
Anle SHEN
2
;
Yejian WANG
2
;
Yanqiong WANG
1
;
Hao LI
1
;
Yanfang GUO
3
;
Youjun WANG
1
;
Xinyan SUN
1
Author Information
1. Clinical Research Center，Shanghai Children’s Medical Center，Shanghai Jiao Tong University School of Medicine，Shanghai 200127，China
2. Dept. of Clinical Pharmacy，Shanghai Children’s Medical Center，Shanghai Jiao Tong University School of Medicine，Shanghai 200127，China
3. Dept. of Pediatrics，Gongli Hospital of Shanghai Pudong New Area，Shanghai 200120，China
- Publication Type:Journal Article
- Keywords:
industry-university-research collaborative innova-
- From:
China Pharmacy
2026;37(2):137-141
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To explore a model for constructing a platform for medical institution formulation and provide insights for promoting their development. METHODS By systematically reviewing the development status and challenges of medical institution preparations in China， and based on the theory of industry-university-research collaborative innovation， the organizational structure， collaborative processes， and safeguard mechanisms of the platform were designed. RESULTS & CONCLUSIONS Medical institution formulations in China mainly faced challenges such as weak research and development （R&D） capacity， uneven quality standards， and blocked transformation pathways. This study established a full-chain， whole- industry collaborative innovation network covering the government， medical institutions， universities/research institutes， pharmaceutical enterprises， and the market， forming a new “government-industry-university-research-application” five-in-one platform model for medical institution formulations. By establishing mechanisms such as multi-entity collaborative cooperation， full- chain intellectual property management， contribution-based benefit distribution， staged risk-sharing， and third-party evaluation， the model clarified the responsibilities and collaborative pathways of all parties. The new model highlights the whole-process transformation of clinical experience-based prescriptions， enabling precise alignment between clinical needs and technological R&D， as well as between preparation achievements and industrial transformation. While breaking down the barriers of traditional platform construction， it effectively achieves optimal resource allocation and complementary advantages， addresses problems emerging in the development of medical institution preparations， and provides reference value for the formulation of relevant systems.
